DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/phrg4s/irribow) has announced the addition of the "Irribow (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023" report to their offering.
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Irribow (ramosetron) is a product that was developed and is marketed by Astellas Pharma, and is available only in Japan for the treatment of males with IBS-D. In July 2014, Astellas announced that it had submitted an sNDA for Irribow for the treatment of females with IBS-D to the Ministry of Health, Labor and Welfare (MHLW) in Japan (Astellas Pharma, press release, July 14, 2014).
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
3.1 Etiology and Pathophysiology
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice
5 Competitive Assessment
6 Irribow (ramosetron)
6.4 SWOT Analysis
For more information visit http://www.researchandmarkets.com/research/phrg4s/irribow